Search

Your search keyword '"Spanswick V"' showing total 22 results

Search Constraints

Start Over You searched for: Author "Spanswick V" Remove constraint Author: "Spanswick V" Search Limiters Full Text Remove constraint Search Limiters: Full Text
22 results on '"Spanswick V"'

Search Results

1. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

2. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

3. Body composition and lung cancer-associated cachexia in TRACERx

4. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

5. Genomic–transcriptomic evolution in lung cancer and metastasis

6. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

7. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

8. The evolution of lung cancer and impact of subclonal selection in TRACERx

9. P1460: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA

10. P1459: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA (B-NHL), AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL)

11. 866P ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced (LA) squamous cell carcinoma of the head and neck (HNSCC)

12. 979TiP POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck

13. 922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas

14. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin

19. Evidence for different mechanisms of ‘unhooking’ for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples

20. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin

21. Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.

22. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay.

Catalog

Books, media, physical & digital resources